within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AX09_Lamotrigine;

model Lamotrigine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.98,
    Cl = 6.5e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.00136,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008666666666666666,
    Tlag = 1200);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lamotrigine</td></tr><tr><td>ATC code:</td><td>N03AX09</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.36</td><td>L</td></tr>
    <tr><td>clearance:</td><td>39</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lamotrigine is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder. It is approved for the prevention and control of seizures and for the maintenance treatment of bipolar I disorder. Lamotrigine stabilizes neuronal membranes by inhibiting voltage-sensitive sodium channels.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects, both male and female, following oral administration of lamotrigine.</p><h4>References</h4><ol><li><p>Chan, V, et al., &amp; Tett, SE (2001). Population pharmacokinetics of lamotrigine. <i>Therapeutic drug monitoring</i> 23(6) 630–635. DOI:<a href=\"https://doi.org/10.1097/00007691-200112000-00006\">10.1097/00007691-200112000-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11802095/\">https://pubmed.ncbi.nlm.nih.gov/11802095</a></p></li><li><p>Yang, H, et al., &amp; Mei, S (2024). Population Pharmacokinetics of Lamotrigine and Its N2-Glucuronide Metabolite in Chinese Patients With Epilepsy. <i>Therapeutic drug monitoring</i> 46(5) 649–657. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000001207\">10.1097/FTD.0000000000001207</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38666475/\">https://pubmed.ncbi.nlm.nih.gov/38666475</a></p></li><li><p>Jacob, S, &amp; Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. <i>Drugs in R&amp;D</i> 16(4) 303–316. DOI:<a href=\"https://doi.org/10.1007/s40268-016-0148-6\">10.1007/s40268-016-0148-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27766590/\">https://pubmed.ncbi.nlm.nih.gov/27766590</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N03AX09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lamotrigine;
